Human genetics studies demonstrate that people who harbor loss of function PCSK9 mutations have low LDL-C levels and decreased risk of CAD [15, 16], while gain of function PCSK9 carriers show the opposite effects [17, 18]. This evidence concerns the gene PCSK9 and coronary artery disorder.